CClinicalTrials.gg
CompletedNCT04322994Updated Mar 27, 2025Results posted

THRIVE Use in Pediatric Populations- Multi Site

An interventional study of Transnasal Humidified Rapid-Insufflation Ventilatory Echange in Oxygen Deficiency, Desaturation of Blood and Hypoventilation, sponsored by Stanford University. Completed at 5 sites in United States. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Study summary

THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia. The use of high-flow nasal cannula oxygen supplementation during anesthesia for surgical procedures has been a recent development in the adult population, with limited data analyzing the pediatric population. This study will determine whether high flow nasal cannula oxygen supplementation during surgical or endoscopic procedures can prevent desaturation events in children under anesthesia and improve the outcomes of that surgery.

02

Conditions studied

  • Oxygen Deficiency
  • Desaturation of Blood
  • Hypoventilation
  • Anesthesia; Adverse Effect
03

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Pediatric patients less than 18 years of age undergoing general anesthesia for procedures or surgeries

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Absence of parent or legal guardian able to provide written consent for study participation
  • Anatomical or surgical contraindications (epistaxis, basilar skull fractures or abnormalities, nasal surgery or obstruction, nasal fractures, nasal vascular abnormalities), tracheostomy tube
  • Emergent surgery for which application of HFNC might delay surgery or might result in increased aspiration risk.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • No intervention
    Control

    Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.

  • Experimental
    Intervention

    Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives. Intervention: Device: High-flow nasal cannula

    Device: Transnasal Humidified Rapid-Insufflation Ventilatory Echange

Interventions

  • DeviceTransnasal Humidified Rapid-Insufflation Ventilatory Echange

    The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.

05

What researchers measure

Primary outcomes

  1. Number of Participants With 4% Decrease From Baseline in Oxygen Desaturation Index

    Oxygen desaturation index is defined as a 4% decrease in saturation from a 120 second rolling mean for greater than 10 seconds; data were recorded every 2 seconds while the procedure was being performed.

    Time frame: Duration of surgery or procedure, which is generally less than 2 hours

  2. Number of Participants With Desaturations <90%

    Relative incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second adjusted for post surgical diagnosis; data were recorded every 2 seconds while the procedure was being performed.

    Time frame: Duration of surgery or procedure, which is generally less than 2 hours

  3. Number of Participants Who Ever Either Fall Below 90% O2 or Drop 4% Below Baseline Saturation

    Relative incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second adjusted for post surgical diagnosis; data were recorded every 2 seconds while the procedure was being performed. Participants who experienced both a fall below 90% O2 and a 4% drop below baseline saturation are reported as having more than 1 event.

    Time frame: Duration of surgery or procedure, which is generally less than 2 hours

Secondary outcomes

  1. Time-normalized Area Under Curve (AUC) of Desaturations <90%

    Duration of oxygen desaturation less than 90% as measured by pulse oximetry by second by analyzing area under curve less than 90% (in those participants who experienced desaturation less than 90%), normalized as area under the curve / total time.

    Time frame: Duration of surgery or procedure, which is generally less than 2 hours

  2. Number of Participants With Surgical Interruptions Due to Desaturation

    Number of surgical interruptions due to desaturation defined by a pause in surgical procedures due to need to provide airway intervention to improve patient's oxygen saturation, normalized to case length. Airway interventions may include jaw thrust, bag mask ventilation, and/or endotracheal intubations.

    Time frame: Duration of surgery or procedure, which is generally less than 2 hours

  3. Minimum Oxygen Saturation as a Measure of Desaturation Severity

    Number of participants categorized by lowest oxygen saturation level during surgery (nadir). Lower saturation levels correspond to a lower level of oxygen in red blood cells.

    Time frame: Duration of surgery or procedure by second, which is generally less than 2 hours

Other outcomes

  1. Gas Pain or Bloating

    Incidence of gas pain or bloating as measured by post-operative survey

    Time frame: Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

  2. Nasal Irritation

    Incidence of nasal irritation as measured by post-operative survey

    Time frame: Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

  3. Sinus Pressure / Pain

    Incidence of sinus pressure and/or pain as measured by post-operative survey

    Time frame: Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

  4. Headache

    Incidence of headache as measured by post-operative survey

    Time frame: Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

  5. Other Adverse Events

    Other adverse events as measured by post-operative survey

    Time frame: Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

06

Results

Posted Mar 27, 2025

Participant flow

Participants were recruited from six pediatric sites (Lucile Packard Children's Hospital, Cincinnati Children's hospital, Lurie Children's Hospital, University of Virginia Children's Hospital, Massachusetts Eye and Ear Infirmary, and Boston Children's Hospital between October 2020 and January 2024. The first participant was enrolled on October 21, 2020 and the last participant was enrolled in January 19, 2024.

Participant flow — Overall Study
MilestoneControlHigh-flow Nasal Cannula
Started8887
Completed7173
Not completed1714

Outcome measures

PrimaryNumber of Participants With 4% Decrease From Baseline in Oxygen Desaturation Index

Oxygen desaturation index is defined as a 4% decrease in saturation from a 120 second rolling mean for greater than 10 seconds; data were recorded every 2 seconds while the procedure was being performed.

Time frame:
Duration of surgery or procedure, which is generally less than 2 hours
Reported as:
Count of participants · Participants
Number of Participants With 4% Decrease From Baseline in Oxygen Desaturation Index
ParticipantsControlHigh-flow Nasal Cannula
Any event1811
1 event139
2+ events52
Statistical analysis
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.18 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.26 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
PrimaryNumber of Participants With Desaturations <90%

Relative incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second adjusted for post surgical diagnosis; data were recorded every 2 seconds while the procedure was being performed.

Time frame:
Duration of surgery or procedure, which is generally less than 2 hours
Reported as:
Count of participants · Participants
Number of Participants With Desaturations <90%
ParticipantsControlHigh-flow Nasal Cannula
Any event1711
1 event89
2+ events92
Statistical analysis
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.26 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.08 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
PrimaryNumber of Participants Who Ever Either Fall Below 90% O2 or Drop 4% Below Baseline Saturation

Relative incidence of oxygen desaturation less than 90% as measured by pulse oximetry by second adjusted for post surgical diagnosis; data were recorded every 2 seconds while the procedure was being performed. Participants who experienced both a fall below 90% O2 and a 4% drop below baseline saturation are reported as having more than 1 event.

Time frame:
Duration of surgery or procedure, which is generally less than 2 hours
Reported as:
Count of participants · Participants
Number of Participants Who Ever Either Fall Below 90% O2 or Drop 4% Below Baseline Saturation
ParticipantsControlHigh-flow Nasal Cannula
Any event1913
1 event33
2+ events1610
Statistical analysis
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.28
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.38 (The a priori threshold for statistical significance was 0.05.)
SecondaryTime-normalized Area Under Curve (AUC) of Desaturations <90%

Duration of oxygen desaturation less than 90% as measured by pulse oximetry by second by analyzing area under curve less than 90% (in those participants who experienced desaturation less than 90%), normalized as area under the curve / total time.

Time frame:
Duration of surgery or procedure, which is generally less than 2 hours
Reported as:
Mean · % of blood oxygen saturation
Time-normalized Area Under Curve (AUC) of Desaturations <90%
% of blood oxygen saturationControlHigh-flow Nasal Cannula
Time-normalized Area Under Curve (AUC) of Desaturations <90%0.3 ± 0.910.28 ± 1.19
Statistical analysis
  • Control vs High-flow Nasal Cannula · t-test, 2 sided · p = 0.88 (The a priori threshold for statistical significance was 0.05.)
SecondaryNumber of Participants With Surgical Interruptions Due to Desaturation

Number of surgical interruptions due to desaturation defined by a pause in surgical procedures due to need to provide airway intervention to improve patient's oxygen saturation, normalized to case length. Airway interventions may include jaw thrust, bag mask ventilation, and/or endotracheal intubations.

Time frame:
Duration of surgery or procedure, which is generally less than 2 hours
Reported as:
Count of participants · Participants
Number of Participants With Surgical Interruptions Due to Desaturation
ParticipantsControlHigh-flow Nasal Cannula
Any event147
1 event115
2+ events32
Statistical analysis
  • Control vs High-flow Nasal Cannula · Chi-squared, Corrected · p = 0.14 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
  • Control vs High-flow Nasal Cannula · Chi-squared · p = 0.21 (The a priori threshold for statistical significance was 0.05.)Chi-squared test of independence
SecondaryMinimum Oxygen Saturation as a Measure of Desaturation Severity

Number of participants categorized by lowest oxygen saturation level during surgery (nadir). Lower saturation levels correspond to a lower level of oxygen in red blood cells.

Time frame:
Duration of surgery or procedure by second, which is generally less than 2 hours
Reported as:
Count of participants · Participants
Minimum Oxygen Saturation as a Measure of Desaturation Severity
ParticipantsControlHigh-flow Nasal Cannula
0-50% O2 saturation22
50-70% O2 saturation32
70-90% O2 saturation127
90-100% O2 saturation5462
Other pre-specifiedGas Pain or Bloating

Incidence of gas pain or bloating as measured by post-operative survey

Time frame:
Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

Results for this outcome have not been posted.

Other pre-specifiedNasal Irritation

Incidence of nasal irritation as measured by post-operative survey

Time frame:
Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

Results for this outcome have not been posted.

Other pre-specifiedSinus Pressure / Pain

Incidence of sinus pressure and/or pain as measured by post-operative survey

Time frame:
Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

Results for this outcome have not been posted.

Other pre-specifiedHeadache

Incidence of headache as measured by post-operative survey

Time frame:
Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

Results for this outcome have not been posted.

Other pre-specifiedOther Adverse Events

Other adverse events as measured by post-operative survey

Time frame:
Evaluated postoperatively in post-anesthesia recovery unit prior to discharge, which is about 60 minutes postoperatively

Results for this outcome have not been posted.

Adverse events

Collected over Up to 2 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/88 (0%)0/88 (0%)0/88 (0%)
High-flow Nasal Cannula0/87 (0%)0/87 (0%)0/87 (0%)

Baseline characteristics

Participants who completed the protocol.

Age, Continuous
Age, Continuous(years)ControlHigh-flow Nasal CannulaTotal
Mean5.6 ± 5.24.7 ± 5.15.1 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)ControlHigh-flow Nasal CannulaTotal
Female282048
Male435396
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ControlHigh-flow Nasal CannulaTotal
White444387
Black123
Hispanic131831
Asian527
Multirace246
Missing6410
Region of Enrollment
Region of Enrollment(Participants)ControlHigh-flow Nasal CannulaTotal
United States7173144
07

Study locations

5 sites
  • Lucile Packard Children's Hospital Stanford
    Palo Alto, California 94304, United States
  • Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Massachussetts Eye and Ear Harvard Medical School
    Boston, Massachusetts 02114, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • The University of Virginia
    Charlottesville, Virginia 22903, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Oct 8, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT04322994
Lead sponsor
Stanford University
Collaborators
Nationwide Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Boston Children's Hospital, UC Davis Children's Hospital
Responsible party
Thomas Caruso (Clinical Associate Professor, Stanford University) — Principal investigator
First posted
Mar 26, 2020
Start date
Oct 21, 2020
Primary completion
Jan 19, 2024
Completion
Jan 19, 2024
Results posted
Mar 27, 2025
Last update
Mar 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion